


## **SYMPOSIUM IV, June 15, 2017: DNA targeting in the age of genomics**




### ***PROF JOHN HARTLEY***

***Director Cancer Research, UK Drug-DNA-Interaction Research Group, UCL Cancer Institute, London, UK***

John Hartley is Professor of Cancer Studies at UCL. He is also Director of the Cancer Research UK Drug-DNA Interactions Research Group and Co-Lead of the UCL Experimental Cancer Medicine Centre. Prior to joining UCL he was a Visiting Fellow at the National Cancer Institute, USA and an Alberta Heritage Research Fellow at the University of Alberta, Canada.

John has a B.Sc. in Biochemistry and a Ph.D. in Experimental Chemotherapy from the University of Manchester. He has 300 publications in the fields of molecular and clinical pharmacology, DNA damage and repair, drug design and development, and cancer therapeutics.

He was one of the founders of Spirogen Ltd, which was acquired by Astazeneca in 2013, and is currently Director of Preclinical Development. He is also an Advisor to ADC Therapeutics. He is a Fellow of both the Royal Societies of Biology and Chemistry and is an Honorary Member of the Royal College of Radiologists. He is also Chair of the Protocol Safety and Review Board of Cancer Research UK.



### ***YVES POMMIER, M.D., PH.D. NCI***

***Center for Cancer Research – National Cancer Institute, Bethesda, MD USA***

Dr. Pommier has been at the NIH since 1981. He is the Chief of the Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, co-Chair of the Discovery Committee of the NCI Experimental Therapeutics Program (NExT) and member of the Molecular Target steering committee at the NCI-Center for Cancer Research. Dr. Pommier is also Honorary Professor of the Shanghai Institute Materia Medica, Chinese Academy of Sciences. Dr. Pommier has received an NIH Merit Award for his role in elucidating the function of topoisomerases as targets for anticancer drugs and several Federal Technology Transfer Awards for his discoveries of DNA topoisomerase, HIV-1 integrase and cell cycle checkpoint inhibitors. Three of his drugs are in clinical trial. Dr. Pommier serves as Senior Editor for Cancer Research, Therapeutics, Targets, and Chemical Biology section. He also served as Chair for 2004-2005 Gordon conferences on the Molecular Therapeutics of Cancer and was founding organizer of the “International conferences on retroviral integrase: molecular biology

and pharmacology” in 1995, 2001, 2008 and 2014, Dr. Pommier has been nominated as Chair for the 2016 and 2018 Gordon conferences on DNA Topoisomerases in Biology & Medicine. Dr. Pommier received the “Paul Ehrlich lecture award” from the French Society of Therapeutic Chemistry in 2005 based on his discovery of the interfacial inhibition concept. He has authored over 600 publications and holds over 30 patents for inhibitors of DNA topoisomerases, Tyrosyl-DNA phosphodiesterase, checkpoint inhibitors and HIV-1 integrase inhibitors.